Understanding incidence and outcomes of testicular and ovarian germ cell tumors from 2000–2017 using population-based cancer registries.

DOI: 10.1200/jco.2025.43.5_suppl.649 Publication Date: 2025-02-18T14:32:12Z
ABSTRACT
649 Background: Both testicular (TGCT) and ovarian germ cell tumors (OGCT) originate from a common primordial lineage prior to differentiation into sperm or eggs share several features. While TGCT are extensively studied, less is known about OGCT but given the relative rarity of both OGCT, we aimed comprehensively assess current landscape these diseases using population-based cancer registries that surveil entire civilian population US. Importantly, this analysis includes all data 2000 2017 therefore not subject impacts on reporting during COVID-19 pandemic in Methods: We accessed available year forward Surveillance, Epidemiology, End Results (SEER) National Program Cancer Registries (NPCR) registry networks obtain information incidence outcomes OGCT. NPCR+SEER was utilized characterize nation-wide patterns according demographic features histologic type, SEER21 describe age-specific patterns, SEER18 SEER9 long-term diagnosis birth. Detailed descriptive were performed. Age-adjusted rates (AAIRs) temporal trends calculated overall stratified by race/ethnicity histology. Observed survival also assessed Results: TGCTs far more than OGCTs majority GCTs occurred adolescents young adults. The AAIRs greatest NH white men for Hispanic White women. Seminoma most histology TGCT, dysgerminoma For drastic increases noted American Indian/Alaska Native men, whereas relatively stable non-Hispanic men. similar amongst racial/ethnic groups. found observed Black with worse other groups, comparable. A pronounced finding seen women experienced compared Regarding histology, those seminoma had better NSGCT/non-dysgerminoma. Conclusions: present contemporary comprehensive assessment US 2000-2017, pandemic. identified various differences within between which highlights opportunities intervene.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)